mm111

  1. T

    Merrimack To Present At BIO On The Development Of MM-111, A Novel Bispecific ErbB2/Er

    Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois. Designed to specifically inhibit ErbB3 signaling in ErbB2 over-expressing...
Back
Top